CDK
Los inhibidores de las quinasas dependientes de ciclina (CDK) son compuestos que bloquean la actividad de las CDK, un grupo de quinasas de proteínas que regulan el ciclo celular, la transcripción y otros procesos celulares. Las CDK se activan al unirse a las ciclinas, y su actividad es crucial para la progresión de las células a través de las diferentes fases del ciclo celular. Inhibir las CDK puede detener la división celular, provocando la detención del ciclo celular y la apoptosis, especialmente en células cancerosas donde las CDK a menudo están desreguladas. Los inhibidores de CDK se utilizan ampliamente en la investigación del cáncer y tienen un potencial terapéutico en el tratamiento de varios tipos de cáncer. En CymitQuimica, ofrecemos una selección completa de inhibidores de CDK de alta calidad para apoyar su investigación en el control del ciclo celular, el cáncer y el desarrollo terapéutico.
Se han encontrado 546 productos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
WAY-322243
CAS:WAY-322243 has antibacterial and anti-inflammatory activity and has an inhibitory effect on CLK-1, which can be used to study Alzheimer's disease.Fórmula:C18H18N2O2SPureza:99.88%Forma y color:SoildPeso molecular:326.41JH-XI-10-02
CAS:JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.Fórmula:C53H69N5O9Pureza:98%Forma y color:SolidPeso molecular:920.161JWZ-5-13
JWZ-5-13 is an effective CDK7 PROTAC degrader that significantly degrades CDK7 via the ubiquitin-proteasome system. JWZ-5-13 also exhibits antitumor activity.Fórmula:C54H66N10O6SPeso molecular:982.48875Cimpuciclib
CAS:Cimpuciclib is a cyclin-dependent kinase(CDK) inhibitor and antineoplastic.Fórmula:C30H35FN8OForma y color:SolidPeso molecular:542.663Cdk2/Cyclin Inhibitory Peptide II
CAS:Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a CDK2 inhibitor, demonstrates dose-dependent cytotoxic effects on U2OS osteosarcoma cells [1].Fórmula:C110H200N48O25Forma y color:SolidPeso molecular:2595.07CPS2
CAS:CPS2: potent, selective PROTAC CDK2 degrader. IC50=24nM, targets acute myeloid leukemia research.Fórmula:C38H42N12O10S2Forma y color:SolidPeso molecular:890.943-Methylthienyl-carbonyl-JNJ-7706621
CAS:Potent CDK inhibitor 3-Methylthienyl-carbonyl-JNJ-7706621, IC50: CDK1=6.4nM, CDK2=2nM, GSK-3=0.041μM; moderate on CDK4/VEGF-R2/FGF-R2.Fórmula:C14H14N6O3S2Forma y color:SolidPeso molecular:378.43CDK7-IN-7
CAS:CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).Fórmula:C20H20BrF3N6O2Forma y color:SolidPeso molecular:513.319YKL-5-124 TFA
CAS:YKL-5-124 TFA is a potent CDK7 inhibitor (IC50: 53.5 nM), more than 100x selective over CDK9/2, not active on CDK12/13, and disrupts the cell cycle.Fórmula:C30H34F3N7O5Forma y color:SolidPeso molecular:629.63IV-361
CAS:IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1Fórmula:C23H32FN5O2SiForma y color:SolidPeso molecular:457.625EGFR/CDK2-IN-2
EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.Fórmula:C49H32N12O2S2Pureza:98%Forma y color:SolidPeso molecular:884.99Multi-target kinase inhibitor 2
Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 valuesPureza:98%Forma y color:Odour SolidBSJ-03-204 triTFA
BSJ-03-204 triTFA is a potent and selective Cereblon- and CDK-targeted PROTAC (PROteolysis TArgeting Chimera) featuring Palbociclib-based ligands for theFórmula:C49H51F9N10O14Pureza:98%Forma y color:SolidPeso molecular:1174.97CDK2/PIM1-IN-1
CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.Forma y color:Odour SolidCDK7-IN-1
CAS:CDK7-IN-1, analog of YKL-5-124, inhibits cdk7 with IC50 < 100 nM.Fórmula:C28H35N7O3Forma y color:SolidPeso molecular:517.634Olomoucine
CAS:Olomoucine hinders Cdk2, Cdc2, CDK5, ERK1, regulates the cell cycle, and fights melanoma; IC50s: 3-25 µM.
Fórmula:C15H18N6OPureza:99.77%Forma y color:White Crystalline PowderPeso molecular:298.34XY028-133
CAS:XY028-133 is a PROTAC-based CDK4/6 degrader for the study of tumors.
Fórmula:C53H67N11O7SPureza:97.11%Forma y color:SolidPeso molecular:1002.23BSJ-04-132
Selective Cdk4 degrader. Degrades Cdk4 in Molt-4 cells, with no effect on Cdk6 levels. Displays cereblon-dependent degradation.Forma y color:LiquidPROTAC FLT3/CDKs degrader-1
PROTACFLT3/CDKs degrader-1 (Compound C3) is an agent that degrades cyclin-dependent kinase (CDK2 with a DC50 of 18.73 nM) and FMS-like tyrosine kinase 3 (FLT3). It induces differentiation in HL-60 cells, achieving a 72.77% differentiation rate at 6.25 nM, and inhibits proliferation of acute myeloid leukemia (AML) cells, with an IC50 ranging from 2.9 to 37 nM. PROTACFLT3/CDKs degrader-1 demonstrates potential for improving the treatment of AML.Fórmula:C40H42N12O5Peso molecular:770.34011CDK6/9-IN-1
CAS:CDK6/9-IN-1, an oral dual inhibitor of CDK6/9, has IC50s of 40.5nM (CDK6) and 39.5nM (CDK9).Fórmula:C22H25ClN8OForma y color:SolidPeso molecular:452.95CDK12/13-IN-2
CDK12/13-IN-2 (Compound 24) is a covalent inhibitor of CDK12 and CDK13, exhibiting IC50 values of 15.5 nM and 12.2 nM, respectively. It effectively inhibits the proliferation of breast cancer cells and can be utilized in the research of triple-negative breast cancer.Fórmula:C24H22FN7O2Forma y color:SolidPeso molecular:459.48BLINK15
BLINK15 is a blood-brain barrier-permeable Cdk5 inhibitor. It reduces CDK5 activity in CDK5/p35 (IC50= 29.34 nM) and CDK5/p25 (IC50= 12.08 nM) complexes. Additionally, BLINK15 exhibits antidiabetic and neuroprotective effects. It lowers blood glucose levels in type 2 diabetes (T2D) mice, enhances cognitive abilities, and diminishes neurodegenerative lesions.Forma y color:Odour SolidMaleimide-PEG8-Val-Ala-PAB-SNS032
Maleimide-Val-Ala-PAB-SNS032 is a conjugated compound used as an ADC toxin and linker. SNS032 acts as a CDK inhibitor, reducing cancer cell viability and arresting the cell cycle at the G1/S phase. Maleimide-Val-Ala-PAB functions as a cleavable ADC linker. Maleimide-Val-Ala-PAB-SNS032 is utilized in the synthesis of ADC molecules.Fórmula:C59H87N9O18S2Peso molecular:1273.56105FDA-Approved Kinase Inhibitor Library
A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.
Forma y color:Liquidbio-THZ1
CAS:bio-THZ1 is a biotinylated version of THZ1. THZ1 is a selective and irreversibly covalent CDK7 inhibitor (IC50: 3.2 nM).Fórmula:C52H65ClN12O8SPureza:98%Forma y color:SolidPeso molecular:1053.67PP-C8
PP-C8: PROTAC CDK12-Cyclin K degrader with DC50s 416/412 nM; synergizes with PARP inhibitor against TNBC.Fórmula:C43H51FN12O7Forma y color:SolidPeso molecular:866.94CDK1-IN-2
CAS:CDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM.Fórmula:C17H11ClN2OPureza:98.53%Forma y color:SoildPeso molecular:294.73Ref: TM-T64373
1mg50,00€5mg107,00€10mg170,00€25mg354,00€50mg567,00€100mg810,00€500mg1.644,00€1mL*10mM (DMSO)103,00€CDK4/6-IN-23
CDK4/6-IN-23 (Compound 42) is a potent and selective inhibitor of CDK4/6, displaying an IC50 of 11 nM for CDK6. This compound significantly activates immune cells and enhances IL-3 production. In mice undergoing 5-FU chemotherapy, CDK4/6-IN-23 demonstrates dual bone marrow protection and immunomodulatory effects.Fórmula:C32H34FN7O4Forma y color:SolidPeso molecular:599.655CDK12-IN-4
CAS:CDK12-IN-4 is a pyrazolotriazine that inhibits CDK12 (IC50: 0.641 μM) with high ATP (2 mM) and spares CDK2/Cyclin E and CDK9/Cyclin T1 (IC50: >20 μM).Fórmula:C20H20F2N8OForma y color:SolidPeso molecular:426.432CDK4/6-IN-11
CAS:CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader.Fórmula:C43H49N11O7Forma y color:SolidPeso molecular:831.92CDK12-IN-6
CAS:CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).Fórmula:C20H21F2N9Forma y color:SolidPeso molecular:425.448NecroIr2
NecroIr2, an iridium(III) compound, induces necroptosis in Cisplatin-resistant A549R lung cancer cells and disrupts mitochondria.Fórmula:C46H30ClIrN6O2Forma y color:SolidPeso molecular:926.44Cell Cycle Compound Library
A unique collection of xnum cell cycle related compounds for high throughput screening (HTS) and high content screening (HCS);
Forma y color:Odour Solid[pSer2, pSer5, pSer7]-CTD TFA
Substrate '[pSer2, pSer5, pSer7]-CTD (TFA)' for CDK7 phosphorylates RNA Pol II CTD at ser2, 5, 7.Fórmula:C98H138F3N21O39Pureza:98%Forma y color:SolidPeso molecular:2291.25PROTAC CDK9 degrader 4
CAS:PROTAC CDK9 degrader 4 is a CDK9 degrader that targets transcriptional regulation and has potential anticancer activity.Fórmula:C43H56N10O5Forma y color:SolidPeso molecular:792.97Abemaciclib metabolite M18
CAS:Abemaciclib M18 (LSN3106729), a potent CDK inhibitor with antitumor action, used in a PROTAC to degrade CDK4/6.Fórmula:C25H28F2N8OPureza:98%Forma y color:SolidPeso molecular:494.54JH-XVI-178
CAS:JH-XVI-178: potent CDK8/19 inhibitor with good pharmacokinetics, low clearance, moderate oral bioavailability.Fórmula:C22H22ClN7OForma y color:SolidPeso molecular:435.92BSJ-5-63
CAS:BSJ-5-63 is an effective degrader of CDK12, CDK7, and CDK9. It reduces the protein expression of CDK12, CDK7, CDK9, RNAPII, and Cyclin K, and also decreases the mRNA expression of BRCA1 and BRCA2. BSJ-5-63 exhibits anticancer activity and holds potential for prostate cancer research.Fórmula:C52H74ClN9O6S2Forma y color:SolidPeso molecular:1020.78PROTAC CDK9 degrader-8
PROTAC CDK9 Degrader-8 (Compound 21) is a potent degrader of CDK9 with an IC50 of 0.01 μM, utilized in cancer research [1].Fórmula:C44H52Cl2N10O7Pureza:98%Forma y color:SolidPeso molecular:903.85CDK9/EZH2-IN-1
CAS:CDK9/EZH2-IN-1 is a dual-target inhibitor of CDK9 and EZH2 with IC50 values of 83.9 nM and 108.6 nM, respectively. It induces apoptosis and causes DNA double-strand breaks (DSB). Additionally, CDK9/EZH2-IN-1 inhibits the proliferation of MKN45, MDA-MB-453, and SW620 cancer cells, with respective IC50 values of 136.3 nM, 171.3 nM, and 315.7 nM.Fórmula:C47H59N11O4S2Forma y color:SolidPeso molecular:906.17MeBIO
CAS:MeBIO is an agonist of aryl hydrocarbon receptor, with IC50 of 44 and 55 μM for GSK-3 and CDK1/CyclinB, respectively. MeBIO does not affect GSK-3β.Fórmula:C17H12BrN3O2Pureza:99.64%Forma y color:SolidPeso molecular:370.2Ref: TM-T21966
1mg39,00€5mg74,00€10mg117,00€25mg220,00€50mg354,00€100mg520,00€500mg1.130,00€1mL*10mM (DMSO)86,00€CDK4/6-IN-5
CAS:CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)Fórmula:C22H28ClFN6O4SForma y color:SolidPeso molecular:527.01Eciruciclib
CAS:Eciruciclib is an inhibitor of CDK with antitumor properties.Fórmula:C27H33FN8Pureza:99.73%Forma y color:SolidPeso molecular:488.6CDK7-IN-2 hydrochloride hydrate
CAS:CDK7-IN-2 HCl hydrate is a potent, specific CDK7 enzyme inhibitor with significant anti-cancer effects.Fórmula:C26H42ClN7O4Forma y color:SolidPeso molecular:552.12A-130A
CAS:A-130A is a polycyclic polyether compound belonging to the nigericin group of antibiotics generated by Streptomyces hygroscopicus strain.Fórmula:C47H78O13Pureza:98%Forma y color:SolidPeso molecular:851.11CDK5-IN-1
CAS:CDK5-IN-1: Potent CDK5 inhibitor (<10 nM) used in kidney disease research.Fórmula:C24H25FN6O3SForma y color:SolidPeso molecular:496.56CDK2-IN-20
CDK2-IN-20 (compound 3b), a CDK2 inhibitor, exhibits cytotoxic effects on tumor cells with an IC50 ranging from 5.52-17.09 µM.Pureza:98%Forma y color:Odour SolidCDK9-IN-28
PROTAC CDK9/CycT1 Degrader-1 (compounds 10), a potent CDK9 inhibitor, serves as a target protein ligand for PROTAC synthesis.Fórmula:C32H40N4O6S2Pureza:98%Forma y color:SolidPeso molecular:640.81BSJ-03-204
CAS:BSJ-03-204 is a selective Cdk4/6 degrader.Fórmula:C43H48N10O8Forma y color:SolidPeso molecular:832.9CP-07
CP-07 is a selective and effective PROTAC CDK9 degrader (DC50: 43 nM), demonstrating inhibition of 22RV1 cell proliferation (IC50: 62 nM) and colony formationFórmula:C45H48N6O8Pureza:98%Forma y color:SolidPeso molecular:800.9
